earnings
confidence high
sentiment positive
materiality 0.75
Biogen Q2 revenue $2.59B, GAAP EPS $7.24; raises full-year guidance
BIOGEN INC.
2022-Q1 EPS reported
$9.27
revenue$5,120,900,000
- Q2 total revenue $2,589M, down 7% YoY; MS revenue $1,719M (-4%), SPINRAZA $431M (-14%).
- GAAP diluted EPS $7.24; Non-GAAP diluted EPS $5.25.
- FDA granted Priority Review for lecanemab (Alzheimer's) with decision by Jan 6, 2023; Phase 3 data expected Fall 2022.
- Second positive Phase 3 for zuranolone in PPD; joint U.S. filing for MDD and PPD expected H2 2022.
- Launched BYOOVIZ (biosimilar Lucentis) in U.S.; raised full year 2022 financial guidance.